DALLAS–(BUSINESS WIRE)–CytoSen Therapeutics, a private biopharmaceutical company accelerating
innovation in Natural Killer (NK) cell therapy™, today
announced the appointment of Jason Wilson to the company’s board of
directors. Mr. Wilson, who currently serves as the Chief Financial
Officer of Reata Pharmaceuticals, Inc. (RETA), brings more than 20 years
of experience in corporate finance and life science operations to
“We are very fortunate to have someone of Jason Wilson’s caliber and
experience join the CytoSen Board of Directors,” said Chairman Philip R.
McKee. “Our company and technology development are at critical stages,
and we need experienced leadership at the board level to successfully
implement our strategy and take advantage of the market opportunities
ahead. Jason is a biotech veteran with a proven track record of
execution who brings talent and energy to CytoSen, and has already
developed a solid understanding of our science and opportunities.”
Mr. Wilson joined Reata in 2006, and has played a key role in helping to
grow the company from a startup through its 2016 initial public
offering. He currently leads corporate strategy, finance, accounting,
treasury, human resources, business development, investor relations and
information technology at Reata. Prior to joining Reata, he held
positions as Vice President, Finance & Corporate Controller at Caris
Diagnostics and Senior Manager in the health-sciences group at Ernst &
Young LLP. Mr. Wilson holds a B.B.A. in Accounting from Henderson
University, an M.B.A. from the University of Central Arkansas and is a
About CytoSen’s NK Cell Platform
NK cells play a significant role in the body’s innate immune response,
circulating through the body to rapidly recognize and kill cancerous
cells. CytoSen’s nanoparticle processing technology enables improved and
sustained growth of high-dose NK cells that have high anti-cancer
cytotoxicity as well as increased expansion and activation capabilities.
CytoSen’s lead product, CSTD002-NK, is poised to enter Phase 2 clinical
studies in the U.S. in the first half of 2019 as a best-in-class NK cell
therapy for the treatment of acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS) in HSCT patients.
CytoSen’s technology platform is based on the work of Dean Lee, M.D.,
Ph.D., Director of the Cellular Therapy and Cancer Immunotherapy Program
for Nationwide Children’s Hospital’s Division
of Hematology/Oncology/BMT and Center
for Childhood Cancer and Blood Diseases, and Stefan Ciurea,
M.D., Associate Professor, Department of Stem Cell Transplantation,
Division of Cancer Medicine, The University of Texas MD Anderson Cancer
Center. Data from Phase I/II clinical trials at MDACC demonstrated
compelling results in treating AML.
Dr. Dean Lee’s Role at CytoSen
Co-Founder Dr. Dean Lee has stepped off the CytoSen Corporate Board to
make room for Mr. Wilson. Dr. Lee will continue to serve as Chairman of
CytoSen’s Science Advisory Board as he also continues to concentrate on
his NK cell research at Nationwide Children’s Hospital, where CytoSen
maintains a Sponsored Research relationship. CytoSen chairman McKee said
“I believe Dr. Lee’s ongoing research at NCH will be a big part of our
About CytoSen Therapeutics, Inc.
CytoSen is a private biopharmaceutical company on the front line of
advancing clinical development of next generation NK cells with the
first scalable, therapeutic platform for high dose, cancer-killing NK
cells calibrated to each cancer target while reinforcing immune defenses.
Born from the intersection of cellular immunotherapy and nanotechnology,
CytoSen’s NK cell therapy harnesses the power of the immune system to
Learn more about CytoSen at www.CytoSen.com.